Search Results - glioma

5 Results Sort By:
Interferon Activation Score Is a Biomarker for Immunotherapy in Malignant Glioma Patients (UCLA Case No. 2024-043)
UCLA researchers from the Department of Neurosurgery have characterized immune responses in malignant glioma patients receiving immunotherapy to develop a robust biomarker that will allow prediction of clinical outcomes following treatment. BACKGROUND: Malignant gliomas are the most common primary brain tumors in adults. No cures exist and most gliomas...
Published: 10/23/2024   |   Inventor(s): Robert Prins
Keywords(s): adjuvant therapy, Biomarker, Chemotherapy, Clinical Trial, dendritic cell vaccination, Glioblastoma, Glioma, immune response, Immunotherapy, interferon, malignant glioma
Category(s): Diagnostic Markers > Immunology, Diagnostic Markers > Cancer, Therapeutics > Inflammation And Inflammatory Diseases, Therapeutics > Oncology, Therapeutics > CNS and Neurology
Compounds and Methods for Treating Cancer by Destroying Cancer Stem Cells (UCLA Case No. 2021-286)
Researchers from UCLA’s Department of Chemistry and Biochemistry and the Department of Radiation Oncology have synthesized a set of compounds for the eradication of cancer stem cells. These compounds are predicted to cross the blood brain barrier and show promise as effective interventions for glioblastoma in both in vitro and in vivo assays. BACKGROUND:...
Published: 7/11/2024   |   Inventor(s): Michael Jung, Frank Pajonk
Keywords(s): blood-brain barrier, Brain, Cancer, Cancer stem cells, drug screening, GBM, Glioblastoma, Glioma, new chemical entity
Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology, Therapeutics > Stem Cells And Regenerative Medicine
Targeted Epigenetic Editing as Novel Therapy for Malignant Glioma (UCLA Case No. 2023-047)
UCLA Researchers in the Department of Neurology/Neuro-Oncology and the David Geffen School of Medicine have developed methods for the Cas9-CRISPR mediated epigenetic targeting of malignant glioma, and which results in enhanced chemosensitivity to standard chemotherapeutic agents. BACKGROUND: Malignant gliomas are aggressive brain tumors originating...
Published: 1/17/2024   |   Inventor(s): Serendipity Zapanta Rinonos, Albert Lai
Keywords(s): Brain, Cancer, Cancer stem cells, Chemotherapy, Combination therapy, CRISPR, CRISPR-Cas9, Epigenetics, GBM, Glioma
Category(s): Therapeutics > Oncology, Therapeutics > CNS and Neurology
High Affinity Nanobodies Targeting B7-H3 (CD276) for Treating Solid Tumors
Abstract: CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy.  Investigators at the National...
Published: 5/21/2024   |   Inventor(s): Mitchell Ho, Brad St. Croix, Ruixue Wang, Dan Li
Keywords(s): ADC, Antibody-drug Conjugate, B7-H3, BREAST CANCER, CAR, CD276, chimeric antigen receptor, COLON CANCER, Glioma, HO, lung cancer, Nanobodies, Neuroblastoma, OVARIAN CANCER, Pancreatic Cancer, solid tumors
Category(s): Application > Therapeutics, Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology
Vitamin D Receptor Antagonists for Treating Breast Cancer
Vitamin D receptor (VDR) is a nuclear receptor that is activated by calcitriol, the active form of vitamin D. It is best known for regulating dietary calcium uptake necessary for bone growth, but it also affects cell proliferation and differentiation. Therefore, it was thought that treatment with calcitriol or its derivatives could be useful to treat...
Published: 4/8/2024   |   Inventor(s): Julianna Barsony
Keywords(s): ANTAGONISTS, ANTICANCER, CB7XXX, CBXXXX, CXXXXX, D, EFFECTS, Glioma, Novel, RECEPTOR, Vitamin
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology